Medtronic has announced that its iPro2 continuous glucose monitoring (CGM) system has secured the approval of the Food and Drug Administration (FDA). iPro2 makes professional CGM much easier and aids healthcare providers in obtaining a comprehensive picture of glucose levels of their patients.
iPro2 can help in the identification of hyperglycemia following meals or nocturnal hypoglycemia, which help in making necessary changes in treatments to enhance glucose control. Good control of glucose levels decreases the risk of complications arising from diabetes including kidney failure, blindness, amputation, heart disease, and impotence.
iPro2 performs a three-day assessment and is an easy-to-use system for patients as well as healthcare professionals. The setup is a three-step process made easy by a “Smart” Dock, which brings down the number of components needed and eliminates the need for a PC. Setup includes the insertion of a glucose sensor beneath the skin of the patient, counseling the patient, and connecting the sensor to the iPro2. The patient can go ahead with their usual day-to-day activities and the CGM system records and saves upto 288 glucose level readings every 24 hours.
The iPro2 system can be adapted to any kind of lifestyle as it is tiny, light-weight and has a water-tight design. The patient need not interact with the system. After wearing it for three days, the patient can return the device for upload to the CareLink iPro software. This web-based software provides a report with the glucose data in easy-to-read formats. Using an Internet connection, access can be accomplished to CareLink software and patient data. The user-friendly reports can serve as a teaching tool to educate patients and motivate them to bring about vital changes in diabetes management by tracking the influence of exercise, food, medications and stress on their glucose levels.
Source: http://www.medtronicdiabetes.com